# GLYXAMBI

Product · id `cardio:fdaprod-nda206073` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [openFDA record NDA206073](<https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>), retrieved 8 November 2026. No person wrote or checked this page.

## In plain language

A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.

## Technical summary

Drugs@FDA application NDA206073. Original approval 2015-01-30. Efficacy supplement approvals 2016-12-23, 2019-07-03, 2020-03-30. 2 products listed.

## The registry's words

- Application: NDA206073
- Brand name: GLYXAMBI
- Applicant: BOEHRINGER INGELHEIM
- Active ingredient: EMPAGLIFLOZIN
- Active ingredient: LINAGLIPTIN
- Dosage form: TABLET
- Route: ORAL

## Claims, with the population each applies to

## Context: FDA record read by the openFDA feed

Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### FDA records an approval of NDA206073 on 2015-01-30.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: submissions\[10\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: submissions\[10\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 7 to NDA206073 on 2016-12-23.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: submissions\[8\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: submissions\[8\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 17 to NDA206073 on 2019-07-03.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: submissions\[3\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: submissions\[3\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 21 to NDA206073 on 2020-03-30.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: submissions\[7\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application NDA206073 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206073>
     Locator: submissions\[7\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd.
     How it applies: The decision status as the record writes it.

## Guidance, authorization and access

### Regulatory decision `cardio:fdadec-nda206073-approval`

- Product: GLYXAMBI (`cardio:fdaprod-nda206073`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Approval, 2015-01-30
- Product version: Original application
- Pathway: NDA
- Submission: NDA206073
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-nda206073-approval`

### Regulatory decision `cardio:fdadec-nda206073-s007`

- Product: GLYXAMBI (`cardio:fdaprod-nda206073`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2016-12-23
- Product version: Efficacy supplement 7
- Pathway: NDA
- Submission: NDA206073
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-nda206073-s007`

### Regulatory decision `cardio:fdadec-nda206073-s017`

- Product: GLYXAMBI (`cardio:fdaprod-nda206073`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2019-07-03
- Product version: Efficacy supplement 17
- Pathway: NDA
- Submission: NDA206073
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-nda206073-s017`

### Regulatory decision `cardio:fdadec-nda206073-s021`

- Product: GLYXAMBI (`cardio:fdaprod-nda206073`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2020-03-30
- Product version: Efficacy supplement 21
- Pathway: NDA
- Submission: NDA206073
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-nda206073-s021`

## Connected pages

- Registry active ingredient is this drug: Empagliflozin (`cardio:empagliflozin`)

## Provenance

Content hash: eb4c74477bf8f01ecbe64867fbe4f4cfede56d9aa17756d3d306fd6a5f031495
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
